These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 21240457

  • 21. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D, Chang R, Wang G, Hu B, Qiang Y, Chen Z.
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [Abstract] [Full Text] [Related]

  • 22. Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma.
    Wang S, Akhtar J, Wang Z.
    Tumour Biol; 2015 Sep; 36(10):7797-806. PubMed ID: 25944168
    [Abstract] [Full Text] [Related]

  • 23. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo.
    Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K.
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):267-74. PubMed ID: 19693537
    [Abstract] [Full Text] [Related]

  • 24. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma.
    Lin ZY, Wu CC, Chuang YH, Chuang WL.
    Life Sci; 2013 Sep 03; 93(8):323-8. PubMed ID: 23871804
    [Abstract] [Full Text] [Related]

  • 25. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.
    Ou W, Mulik RS, Anwar A, McDonald JG, He X, Corbin IR.
    Free Radic Biol Med; 2017 Nov 03; 112():597-607. PubMed ID: 28893626
    [Abstract] [Full Text] [Related]

  • 26. A Novel Microtubule-Disrupting Agent Induces Endoplasmic Reticular Stress-Mediated Cell Death in Human Hepatocellular Carcinoma Cells.
    Ho CT, Chang YJ, Yang LX, Wei PL, Liu TZ, Liu JJ.
    PLoS One; 2015 Nov 03; 10(9):e0136340. PubMed ID: 26355599
    [Abstract] [Full Text] [Related]

  • 27. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
    Min SY, Byeon HJ, Lee C, Seo J, Lee ES, Shin BS, Choi HG, Lee KC, Youn YS.
    Int J Pharm; 2015 Oct 15; 494(1):506-15. PubMed ID: 26315118
    [Abstract] [Full Text] [Related]

  • 28. Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
    Liu Y, Wu X, Gao Y, Zhang J, Zhang D, Gu S, Zhu G, Liu G, Li X.
    Int J Nanomedicine; 2016 Oct 15; 11():3891-905. PubMed ID: 27574422
    [Abstract] [Full Text] [Related]

  • 29. TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling.
    Ke X, Zhao Y, Lu X, Wang Z, Liu Y, Ren M, Lu G, Zhang D, Sun Z, Xu Z, Song JH, Cheng Y, Meltzer SJ, He S.
    Oncotarget; 2015 Oct 20; 6(32):32610-21. PubMed ID: 26416455
    [Abstract] [Full Text] [Related]

  • 30. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
    Mao J, Wang D, Wang Z, Tian W, Li X, Duan J, Wang Y, Yang H, You L, Cheng Y, Bian J, Chen Z, Yang Y.
    Cancer Lett; 2016 Sep 28; 380(1):134-43. PubMed ID: 27349166
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.
    Hanaoka H, Nakajima T, Sato K, Watanabe R, Phung Y, Gao W, Harada T, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H.
    Nanomedicine (Lond); 2015 Sep 28; 10(7):1139-47. PubMed ID: 25929570
    [Abstract] [Full Text] [Related]

  • 33. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.
    Yang M, Su Y, Wang Z, Du D, Wei S, Liao Z, Zhang Q, Zhao L, Zhang X, Han L, Jiang J, Zhan M, Sun L, Yuan S, Zhou Z.
    Biochem Pharmacol; 2021 Aug 28; 190():114641. PubMed ID: 34077738
    [Abstract] [Full Text] [Related]

  • 34. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.
    Ma Z, He H, Sun F, Xu Y, Huang X, Ma Y, Zhao H, Wang Y, Wang M, Zhang J.
    J Cancer Res Clin Oncol; 2017 Oct 28; 143(10):1929-1940. PubMed ID: 28536738
    [Abstract] [Full Text] [Related]

  • 35. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
    Zhang L, Marrano P, Kumar S, Leadley M, Elias E, Thorner P, Baruchel S.
    Clin Cancer Res; 2013 Nov 01; 19(21):5972-83. PubMed ID: 23989978
    [Abstract] [Full Text] [Related]

  • 36. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
    Hu M, Wang M, Lu H, Wang X, Fang X, Wang J, Ma C, Chen X, Xia H.
    Oncotarget; 2016 Jul 12; 7(28):43419-43431. PubMed ID: 27270326
    [Abstract] [Full Text] [Related]

  • 37. Auphen and dibutyryl cAMP suppress growth of hepatocellular carcinoma by regulating expression of aquaporins 3 and 9 in vivo.
    Peng R, Zhao GX, Li J, Zhang Y, Shen XZ, Wang JY, Sun JY.
    World J Gastroenterol; 2016 Mar 28; 22(12):3341-54. PubMed ID: 27022216
    [Abstract] [Full Text] [Related]

  • 38. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
    Wang J, Wu Z, Pan G, Ni J, Xie F, Jiang B, Wei L, Gao J, Zhou W.
    Nanomedicine; 2018 Aug 28; 14(6):1949-1961. PubMed ID: 29045824
    [Abstract] [Full Text] [Related]

  • 39. Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine-based amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for treatment of human hepatocellular carcinoma with paclitaxel.
    Miyata R, Ueda M, Jinno H, Konno T, Ishihara K, Ando N, Kitagawa Y.
    Int J Cancer; 2009 May 15; 124(10):2460-7. PubMed ID: 19173297
    [Abstract] [Full Text] [Related]

  • 40. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.